Humana (NYSE:HUM) was upgraded by Jefferies Group from a “hold” rating to a “buy” rating in a report issued on Friday, Marketbeat reports. The firm presently has a $221.00 price target on the insurance provider’s stock. Jefferies Group’s target price would indicate a potential downside of 17.54% from the company’s previous close.

Other analysts have also issued reports about the stock. Credit Suisse Group began coverage on shares of Humana in a research note on Thursday, November 2nd. They set a “neutral” rating and a $256.00 target price for the company. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Morgan Stanley decreased their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a report on Thursday, November 9th. Finally, Cowen restated a “buy” rating and issued a $285.00 price objective on shares of Humana in a report on Wednesday, December 13th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Humana presently has a consensus rating of “Buy” and a consensus price target of $260.10.

Shares of Humana (NYSE:HUM) traded up $2.81 on Friday, hitting $268.02. 1,573,430 shares of the stock were exchanged, compared to its average volume of 1,150,222. The stock has a market capitalization of $38,290.00, a price-to-earnings ratio of 21.10, a P/E/G ratio of 1.70 and a beta of 0.88. Humana has a 1 year low of $186.25 and a 1 year high of $271.99. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business’s revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $3.18 earnings per share. equities analysts forecast that Humana will post 11.63 EPS for the current year.

Humana declared that its Board of Directors has approved a share buyback program on Thursday, December 14th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the insurance provider to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

In other Humana news, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders sold 10,115 shares of company stock valued at $2,501,627 over the last quarter. 0.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in HUM. WFG Advisors LP raised its holdings in Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares in the last quarter. Fieldpoint Private Securities LLC bought a new position in Humana in the third quarter worth about $115,000. Acrospire Investment Management LLC bought a new position in Humana in the second quarter worth about $120,000. Northwestern Mutual Wealth Management Co. raised its holdings in Humana by 139.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after purchasing an additional 325 shares in the last quarter. Finally, ClariVest Asset Management LLC bought a new position in Humana in the third quarter worth about $144,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Humana (HUM) Stock Rating Upgraded by Jefferies Group” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/01/15/humana-hum-stock-rating-upgraded-by-jefferies-group.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related stocks with our FREE daily email newsletter.